Transarterial chemoembolization (TACE), a minimally invasive procedure for liver cancer, is an effective treatment strategy for patients with large, asymptomatic, or multifocal hepatocellular ...

In this review we will discuss TACE, TAE and TOCE in detail. The TACE procedure consists of the injection of anticancer drugs mixed with or without lipiodol into the hepatic artery followed by the ...

Lenvatinib (Lenv) plus tislelizumab (Tis) combined with or without transarterial chemoembolization (TACE) in first-line treatment of unresectable hepatocellular carcinoma (uHCC): A prospective, ...

Combining TACE and SBRT offers a promising treatment for large HCC tumors, addressing TACE's limitations in intermediate-stage cases. Technological advancements have improved SBRT's precision and ...

There's a possible new standard of care on the horizon for unresectable hepatocellular carcinoma (HCC) after years of failed attempts to improve upon the outcomes of the current protocol — stand-alone ...

Please provide your email address to receive an email when new articles are posted on . Postprocedural imaging showed 10% of patients had new portal vein thrombosis after transarterial ...

SAN FRANCISCO -- An immuno-oncology (IO) regimen for intermediate-stage hepatocellular carcinoma (HCC) significantly extended ...

SAN FRANCISCO -- After more than 20 years of trying, systemic therapy for unresectable liver cancer has improved outcomes with transarterial chemoembolization (TACE), a randomized trial showed.

Tick marks indicate censoring of data. No participants had an albumin-bilirubin grade of 3, so this group has not been included in subgroup definitions here. BCLC=Barcelona Clinic Liver Cancer.

A multi-center study on the role of ACSL4 in invasion and metastasis of hepatocellular carcinoma. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a ...

Please provide your email address to receive an email when new articles are posted on . Transarterial chemoembolization plus vitamin K prolonged progression-free survival compared with TACE alone (262 ...